Frontiers in Cardiovascular Medicine

FEBRUARY 5, 2024

Despite developments in circulating biomarker and imaging technology in the assessment of cardiovascular disease, the surveillance and diagnosis of heart transplant rejection has continued to rely on histopathologic interpretation of the endomyocardial biopsy.

Heart Transplant 64

Heart Transplant Transplant Biomarkers Technology 64

Circulation

MARCH 11, 2024

Circulation, Ahead of Print. Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking.

Transplant 45

Transplant Cardiovascular Disease Atrial Fibrillation Pediatrics 45

DAIC

APRIL 30, 2024

Image courtesy of Hideki Kobayashi from Shinshu University milla1cf Tue, 04/30/2024 - 12:53 April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. However, the risk of arrhythmias following this procedure is reportedly high.

Transplant 105

Transplant Heart Transplant Myocardial Infarction Heart Attack 105

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page ASa1109-ASa1109, November 12, 2024. However, the assessment of aerobic capacity in this population still relies on comparisons with people without cardiovascular disease, rather than comparison with the expected aerobic capacity of other Fontan patients. 15.2 - 23.9)

Transplant 40

Transplant Outcomes Exercise Cardiovascular Disease 40

Circulation

FEBRUARY 15, 2024

Circulation, Ahead of Print. BACKGROUND:Clonal hematopoiesis of indeterminate potential (CHIP), a common age-associated phenomenon, associates with increased risk of both hematological malignancy and cardiovascular disease.

Atrial Fibrillation 45

Atrial Fibrillation Diet Myocardial Infarction Cardiovascular Disease 45

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). The Impella CP is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation. It is able to deliver 3.5L/min

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139383-A4139383, November 12, 2024. Background:Immunosuppressive (IS) therapy is currently used as first-line treatment for heart transplant (HTx) rejection. However, they are not without complications, and less toxic therapies are needed. years, males: 58.4%).

Heart Transplant 40

Heart Transplant Transplant Cardiovascular Disease Outcomes 40